William Blair analyst Brandon Vazquez has maintained their bullish stance on RMD stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Brandon Vazquez has given his Buy rating due to a combination of factors including ResMed’s impressive fiscal fourth-quarter performance, which exceeded revenue expectations by $21 million and non-GAAP EPS by $0.05. This strong performance was largely driven by robust mask sales in the Americas and device sales in Europe, Asia, and other regions. Additionally, the company’s gross margins were notably higher than anticipated, benefiting from tariff exemptions and setting a promising gross margin guidance for fiscal 2026.
Furthermore, ResMed’s new primary care physician efforts are beginning to show positive results, with increased demand for CME courses, indicating potential for future sales growth. Despite some bottlenecks in sleep labs, the company is actively investing in solutions to enhance patient experience and streamline treatment processes. With shares trading at a reasonable multiple of fiscal 2026 EPS, Vazquez views the company’s stable revenue and growing profitability as strong indicators for continued success heading into fiscal 2026.
In another report released today, KeyBanc also maintained a Buy rating on the stock with a $298.00 price target.